Interpreting Qiagen (QGEN) International Revenue Trends
UBS Maintains Neutral on Qiagen, Raises Price Target to $50
Qiagen (QGEN) Shareholders Approve Jonathan M Pratt As CEO And Managing Director
Qiagen (QGEN) Stock May Be Fully Priced As Sequencing Project Expands
QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director
Qiagen N.V. (QGEN) Shareholder/Analyst Call Prepared Remarks Transcript
Qiagen N.V. (QGEN) Shareholder/Analyst Call - Slideshow
QIAGEN N.V. Reports Q3 2026 Results and Suspends Outlook Pending Acquisition by EQT Private Equity
Qiagen N.V. Announces Public Takeover Offer from EQT Private Equity at €46.50 Per Share
What Does Qiagen (QGEN) Joining Singapore’s Precision Medicine Program Mean?
Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics
Qiagen (QGEN) Surpasses Q3 Earnings and Revenue Estimates
Qiagen: Q3 Earnings Snapshot
QIAGEN Reports Full Q3 2026 Results
Qiagen Q3 Adj. EPS $0.65, Inline, Sales $548.000M Miss $573.331M Estimate
Do Options Traders Know Something About Qiagen Stock We Don't?
Qiagen (QGEN) On Its €9.7b Takeover Deal Still Looks Fully Valued
Barclays Downgrades Qiagen to Equal-Weight, Lowers Price Target to $53
Citigroup Maintains Neutral on Qiagen, Raises Price Target to $52
QIAGEN N.V. Enters Business Combination Agreement for Planned Tender Offer by Crown NL Bidco B.V. at €46.50 Per Share
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.